首页> 外文期刊>Journal of Endocrinological Investigation: Official Journal of the Italian Society of Endocrinology >Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.
【24h】

Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.

机译:Prader-Willi 综合征中 GH 对 GH 释放六肽 (GHRP-6) 反应性受损。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The aim of this study was to evaluate the GH-releasing activity of a synthetic hexapeptide, GHRP-6, in the Prader-Willi syndrome (PWS). Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 microg/kg, iv) or GHRH (1 microg/kg, iv)+PD (60 or 120 mg for children or adults, po). Moreover, in 11 patients with PWS and in the group of SN, the GH response to at least 2 stimulation tests had been previously determined. GH was analyzed either as mean peak values (GHp, mcg/l), or as the area under the curve (AUC, mcg/l/h) and the net incremental area under the curve (nAUC, mcg/l/h). In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4+/-2.0; AUC: 588+/-113; nAUC: 483+/-108) and GHRH+PD (GHp: 7.3+/-1.8; AUC: 486+/-122; nAUC: 371+/-250) were significantly lower than those observed either in OB (GHRP-6: GHp: 25.7+/-3.2, p<0.003; AUC: 1833+/-305, p<0.005; nAUC: 1640+/-263, p<0.0001. GHRH+PD: GHp: 15.1+/-2.4, p<0.009; AUC: 1249+/-248, p<0.003; nAUC: 918+/-230, p<0.006) or in SN patients (GHRP-6: GHp: 39.1+/-3.1, p<0.0001; AUC: 2792+/-158, p<0.0001; nAUC: 2705+/-165, p<0.00005. GHRH+PD: GHp: 27.5+/-3.7, p<0.0001; AUC: 1873+/-251, p<0.0001; nAUC: 1692+/-219, p<0.0005). Unlike control groups, in PWS patients GH levels after GHRP-6 did not differ from those obtained after GHRH+PD. Interestingly, low IGF-I values were present in all PWS subjects. Furthermore, no patient with PWS showed normal GH response to the previously performed GH stimulation tests. As already reported, GH release after GHRP-6 or GHRH+PD was significantly lower in OB than in SN subjects. In conclusion, our data indicate that: 1) GH response to GHRP-6 is clearly impaired in PWS; 2) the blunted GH responses to the provocative stimuli in PWS are not an artifact of obesity; 3) short stature in PWS is caused by a complex dysfunction of the hypothalamo-pituitary structures.
机译:本研究的目的是评估合成六肽 GHRP-6 在 Prader-Willi 综合征 (PWS) 中的 GH 释放活性。16 例 PWS 患者(7 例男性和 9 例女性,年龄 12.7-38.3 岁)、15 例原发性肥胖 (OB)(7 例男性和 8 例女性,年龄 12.9-42.9 岁)和 8 例矮小正常儿童(SN;3 名男性和 5 名女性,年龄 10.2-14.3 岁)分别接受了 2 次测试,分别接受 GHRP-6(1 μg/kg,iv)或 GHRH(1 μg/kg, iv)+PD(儿童或成人 60 或 120 毫克,po)。此外,在 11 例 PWS 患者和 SN 组中,先前已确定 GH 对至少 2 次刺激试验的反应。GH分析为平均峰值(GHp,mcg/l),或曲线下面积(AUC,mcg/l/h)和曲线下净增量面积(nAUC,mcg/l/h)。在 PWS 受试者组中,GH 对 GHRP-6 (GHp: 11.4+/-2.0;AUC:588+/-113;nAUC:483+/-108)和GHRH+PD(GHp:7.3+/-1.8;AUC:486+/-122;nAUC:371+/-250)显著低于OB中观察到的(GHRP-6:GHp:25.7+/-3.2,p<0.003;AUC:1833+/-305,p<0.005;nAUC:1640+/-263,p<0.0001。GHRH+PD:GHp:15.1+/-2.4,p<0.009;AUC:1249+/-248,p<0.003;nAUC:918+/-230,p<0.006)或SN患者(GHRP-6:GHp:39.1+/-3.1,p<0.0001;AUC:2792+/-158,p<0.0001;nAUC:2705+/-165,p<0.00005。GHRH+PD:GHp:27.5+/-3.7,p<0.0001;AUC:1873+/-251,p<0.0001;nAUC:1692+/-219,p<0.0005)。与对照组不同,在 PWS 患者中,GHRP-6 后的 GH 水平与 GHRH+PD 后获得的水平没有差异。 有趣的是,所有 PWS 受试者都存在低 IGF-I 值。此外,没有 PWS 患者对先前进行的 GH 刺激测试表现出正常的 GH 反应。如前所述,OB 的 GHRP-6 或 GHRH+PD 后 GH 释放显着低于 SN 受试者。总之,我们的数据表明:1)PWS中GH对GHRP-6的反应明显受损;2)PWS中GH对挑衅性刺激的迟钝反应不是肥胖的产物;3)PWS的身材矮小是由下丘脑-垂体结构的复杂功能障碍引起的。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号